High Use of SABAs is Associated with Higher Exacerbation Rate in Dutch Patients with Asthma

Anna Jetske Baron,1– 3 Bertine MJ Flokstra-de Blok,1,2,4 Huib AM Kerstjens,2,3 Gineke Koopmans-Klein,5 David B Price,6,7 Andrea A Sellink,8 Ioanna Tsiligianni,9 Janwillem WH Kocks1,2,6 1General Practitioners Research Institute, Groningen, the Netherlands; 2University of Groningen, University Medical Center Groningen, GRIAC Research Institute, Groningen, the Netherlands; 3University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, the Netherlands; 4University of Groningen, University Medical Center Groningen, Beatrix Children’s Hos... Mehr ...

Verfasser: Baron AJ
Flokstra-de Blok BM
Kerstjens HAM
Koopmans-Klein G
Price DB
Sellink AA
Tsiligianni I
Kocks JWH
Dokumenttyp: Artikel
Erscheinungsdatum: 2021
Reihe/Periodikum: Journal of Asthma and Allergy, Vol Volume 14, Pp 851-861 (2021)
Verlag/Hrsg.: Dove Medical Press
Schlagwörter: asthma / short acting beta2-agonist / saba / primary health care / adverse effects / guidelines / Immunologic diseases. Allergy / RC581-607
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-27408669
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doaj.org/article/ccd3dd6b9cfe4e218b73ec95729eef9e